InsiderTrades.com logo
Wim Souverijns net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Wim Souverijns Biography and Net Worth

Insider of Pharvaris

Dr. Souverijns joined the Company in July 2021 with over 25 years of experience in pharmaceutical portfolio strategic and operational leadership at ObsEva, Celgene, and Amgen.

Dr. Souverijns joined the Company from his most recent position as the Chief Commercial Officer at ObsEva where he was responsible for the commercialization of its women’s health product portfolio. Prior to joining ObsEva, he spent 11 years at Celgene where he contributed to the successful build out of the product portfolio in diverse strategic and operational leadership roles. He developed a broad pharmaceutical background through various international assignments at PwC Consulting and in different market access roles at Amgen, both at the European and global level. Dr. Souverijns holds a degree in bio-engineering from the KU Leuven, Belgium, and obtained a Ph.D. from the same institute.

What is Wim Souverijns' net worth?

The estimated net worth of Wim Souverijns is at least $1.36 million as of May 15th, 2026. Souverijns owns 45,111 shares of Pharvaris stock worth more than $1,359,646 as of June 3rd. This net worth approximation does not reflect any other investments that Souverijns may own. Learn More about Wim Souverijns' net worth.

How do I contact Wim Souverijns?

The corporate mailing address for Souverijns and other Pharvaris executives is , , . Pharvaris can also be reached via phone at 31-71-203-6410 and via email at [email protected]. Learn More on Wim Souverijns' contact information.

Has Wim Souverijns been buying or selling shares of Pharvaris?

During the last quarter, Wim Souverijns has sold $299,200.00 in shares of Pharvaris stock. Most recently, Wim Souverijns sold 10,000 shares of the business's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $29.92, for a transaction totalling $299,200.00. Following the completion of the sale, the insider now directly owns 45,111 shares of the company's stock, valued at $1,349,721.12. Learn More on Wim Souverijns' trading history.

Who are Pharvaris' active insiders?

Pharvaris' insider roster includes Elisabeth Bjork (Director), Robert Glassman (Director), Anne Lesage (Chief Early Development Officer), Anne Lesage (Insider), Peng Lu (Chief Medical Officer), Berndt Modig (Chief Executive Officer, Director (CH)), Viviane Monges (Director), David Nassif (CFO), Anna Nijdam (Insider), and Wim Souverijns (Insider). Learn More on Pharvaris' active insiders.

Are insiders buying or selling shares of Pharvaris?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 209,948 shares worth more than $6,268,140.96. The most recent insider tranaction occured on May, 22nd when insider Anna Nijdam sold 5,501 shares worth more than $169,100.74. Learn More about insider trades at Pharvaris.

Information on this page was last updated on 5/22/2026.

Wim Souverijns Insider Trading History at Pharvaris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2026Sell10,000$29.92$299,200.0045,111View SEC Filing Icon  
See Full Table

Wim Souverijns Buying and Selling Activity at Pharvaris

This chart shows Wim Souverijns's buying and selling at Pharvaris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharvaris Company Overview

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $30.14
Low: $28.80
High: $30.50

50 Day Range

MA: $28.86
Low: $25.34
High: $32.94

2 Week Range

Now: $30.14
Low: $15.91
High: $33.33

Volume

703,962 shs

Average Volume

233,293 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A